“…Aberrant expression of HGF and c-met are found in various tumors of mesenchymal origin such as osteosarcomas, sarcomas of patients with Li ± Fraumeni syndrome, Kaposi sarcomas, melanomas and leukemias (Natali et al, 1993;Naidu et al, 1994;Rong et al, 1995;Ferracini et al, 1995). Similarly, overexpression of c-met and/or HGF was also found in dierent human carcinomas such as bladder, gastric, pancreatic, prostatic and thyroid carcinomas (Ebert et al, 1994;Humphrey et al, 1995;Di Renzo et al, 1995;Joseph et al, 1995). In breast carcinoma patients, overexpression of HGF correlates with poor prognosis (Yamashita et al, 1994).…”